Tis­sue-ag­nos­tic drug de­vel­op­ment: FDA on­col­o­gy cen­ter of­fers draft guid­ance

With the rise of Mer­ck’s Keytru­da and Bay­er’s Vi­t­rakvi, which have won ac­cel­er­at­ed ap­provals over the last five years for ge­net­i­cal­ly-tar­get­ed (rather than tis­sue-tar­get­ed) can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER